Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis (AD)

NCT01927705 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

BIOLOGICAL: FURESTEM-AD Inj.

Sponsor

Kang Stem Biotech Co., Ltd.